down arrow

SELLAS Life Sciences Group, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US81642T2096
USD
1.74
0.35 (25.18%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.521.84

52 Week

0.772.48
Valuation
Technical
Day's Volume

CASH

10.36 M

Shareholding (Mar 2025)

FII

0.42%

Held by 16 FIIs

DII

94.75%

Held by 6 DIIs

Promoter

0.00%

How big is SELLAS Life Sciences Group, Inc.?

22-Jun-2025

As of Jun 18, SELLAS Life Sciences Group, Inc. has a market capitalization of 155.65 million, with net sales of 0.00 million and a net profit of -27.13 million over the latest four quarters. The company's shareholder's funds are 9.46 million, and total assets amount to 19.63 million.

Market Cap: As of Jun 18, SELLAS Life Sciences Group, Inc. has a market capitalization of 155.65 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 0.00 million and a net profit of -27.13 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 9.46 million, while total assets were reported at 19.63 million.

Read More

What does SELLAS Life Sciences Group, Inc. do?

22-Jun-2025

SELLAS Life Sciences Group, Inc. is a biopharmaceutical company focused on developing targeted oncology therapeutics. As of March 2025, it has a market cap of $155.65 million and reported a net profit loss of $6 million.

Overview:<BR>SELLAS Life Sciences Group, Inc. is a biopharmaceutical company focused on developing and commercializing targeted oncology therapeutics in the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 155.65 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.01<BR>Return on Equity: -97.73%<BR>Price to Book: 5.61<BR><BR>Contact Details:<BR>Address: 7 TIMES SQUARE, SUITE 2503, NEW YORK NY: 10036<BR>Tel: 1 646 2005278<BR>Fax: 1 925 4987799<BR>Website: https://www.sellaslifesciences.com/

Read More

Who are in the management team of SELLAS Life Sciences Group, Inc.?

22-Jun-2025

As of March 2022, the management team of SELLAS Life Sciences Group, Inc. includes Ms. Jane Wasman (Independent Chairman), Dr. Angelos Stergiou (President and CEO), Dr. David Scheinberg (Director), and Independent Directors Mr. Robert Van Nostrand and Mr. John Varian. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of SELLAS Life Sciences Group, Inc. includes the following individuals:<BR><BR>- Ms. Jane Wasman, who serves as the Independent Chairman of the Board.<BR>- Dr. Angelos Stergiou, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. David Scheinberg, who is a Director.<BR>- Mr. Robert Van Nostrand, who is an Independent Director.<BR>- Mr. John Varian, who is also an Independent Director. <BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Read More

Is SELLAS Life Sciences Group, Inc. overvalued or undervalued?

25-Jun-2025

SELLAS Life Sciences Group, Inc. is considered overvalued due to a significant downgrade in its investment appeal, reflected by a Price to Book Value of 5.79, a negative Return on Equity of -97.73%, and negative EV to EBITDA and EV to EBIT ratios, despite a strong year-to-date stock performance of 64.42%.

As of 11 May 2023, the valuation grade for SELLAS Life Sciences Group, Inc. moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company appears to be overvalued given its financial metrics, with a Price to Book Value of 5.79 and a Return on Equity (ROE) of -97.73%. Additionally, the EV to EBITDA and EV to EBIT ratios are both negative at -4.75, reflecting the company's loss-making status.<BR><BR>In comparison to peers, SELLAS Life Sciences Group, Inc. has a worse EV to EBITDA ratio than Rezolute, Inc. at -3.4613 and Assembly Biosciences, Inc. at -0.8977, both of which are also categorized as risky. The company's recent stock performance shows a 64.42% year-to-date return, which outperforms the S&P 500's 2.44%, yet this does not mitigate the overall valuation concerns. Therefore, based on the analysis, SELLAS Life Sciences Group, Inc. is considered overvalued.

Read More

Is SELLAS Life Sciences Group, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, SELLAS Life Sciences Group, Inc. shows a mildly bullish trend with daily moving averages indicating positivity, but caution is advised due to bearish weekly MACD and KST, while the stock has underperformed the S&P 500 recently but significantly outperformed it year-to-date.

As of 2 September 2025, the technical trend for SELLAS Life Sciences Group, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating a positive trend. However, the weekly MACD and KST are mildly bearish, suggesting some caution. The Bollinger Bands on a weekly basis are bearish, contrasting with the monthly view which is mildly bullish. The RSI shows no signal on both weekly and monthly time frames, indicating a lack of momentum.<BR><BR>In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -14.81% and -6.94% respectively, while the S&P 500 gained 1.05% and 2.33%. However, year-to-date, the stock has significantly outperformed the benchmark with a return of 54.81% compared to the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 200 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.95

stock-summary
Return on Equity

-100.42%

stock-summary
Price to Book

7.65

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-7 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.25%
0%
-2.25%
6 Months
6.1%
0%
6.1%
1 Year
47.46%
0%
47.46%
2 Years
61.11%
0%
61.11%
3 Years
-34.83%
0%
-34.83%
4 Years
-71.66%
0%
-71.66%
5 Years
-53.1%
0%
-53.1%

SELLAS Life Sciences Group, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is SELLAS Life Sciences Group, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for SELLAS Life Sciences Group, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating a positive trend. However, the weekly MACD and KST are mildly bearish, suggesting some caution. The Bollinger Bands on a weekly basis are bearish, contrasting with the monthly view which is mildly bullish. The RSI shows no signal on both weekly and monthly time frames, indicating a lack of momentum. In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -14.81% and -6.94% respectively, while the S&P 500 gained 1.05% and 2.33%. However, year-to-date, the stock has significantly outperformed the benchmark with a return of 54.81% compared to the S&P 500's 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-16.09%
EBIT to Interest (avg)
-27.64
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.01
Sales to Capital Employed (avg)
0.19
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
20.97%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.79
EV to EBIT
-4.75
EV to EBITDA
-4.75
EV to Capital Employed
-132.71
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-97.73%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (4.83%)

Foreign Institutions

Held by 16 Foreign Institutions (0.42%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -13.79% vs 13.43% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.90",
          "val2": "-6.10",
          "chgp": "-13.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.60",
          "val2": "-5.80",
          "chgp": "-13.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 17.16% vs 9.69% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-31.50",
          "val2": "-37.90",
          "chgp": "16.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-30.90",
          "val2": "-37.30",
          "chgp": "17.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.90
-6.10
-13.11%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-6.60
-5.80
-13.79%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -13.79% vs 13.43% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-31.50
-37.90
16.89%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-30.90
-37.30
17.16%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 17.16% vs 9.69% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About SELLAS Life Sciences Group, Inc. stock-summary
stock-summary
SELLAS Life Sciences Group, Inc.
Pharmaceuticals & Biotechnology
SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.
Company Coordinates stock-summary
Company Details
7 TIMES SQUARE, SUITE 2503 , NEW YORK NY : 10036
stock-summary
Tel: 1 646 2005278
stock-summary
https://www.sellaslifesciences.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."